BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7530933)

  • 1. Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures.
    Peterson PK; Gekker G; Hu S; Chao CC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2465-8. PubMed ID: 7530933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
    Pagano PJ; Chong KT
    J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
    Nottet HS; Oteman MH; Visser MR; Verhoef J
    J Antimicrob Chemother; 1994 Feb; 33(2):366-8. PubMed ID: 7514164
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
    Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
    Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
    Dueweke TJ; Poppe SM; Romero DL; Swaney SM; So AG; Downey KM; Althaus IW; Reusser F; Busso M; Resnick L
    Antimicrob Agents Chemother; 1993 May; 37(5):1127-31. PubMed ID: 7685995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Chong KT; Pagano PJ; Hinshaw RR
    Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
    Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.
    Althaus IW; Chou JJ; Gonzales AJ; Deibel MR; Chou KC; Kezdy FJ; Romero DL; Thomas RC; Aristoff PA; Tarpley WG
    Biochem Pharmacol; 1994 Jun; 47(11):2017-28. PubMed ID: 7516658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delavirdine/protease inhibitor interactions.
    Gilden D
    GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW
    Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.
    Perno CF; Bergamini A; Pesce CD; Milanese G; Capozzi M; Aquaro S; Thaisrivongs S; Tarpley WG; Zon G; D'Agostini C
    J Infect Dis; 1993 Nov; 168(5):1148-56. PubMed ID: 8228348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.
    Vasudevachari MB; Battista C; Lane HC; Psallidopoulos MC; Zhao B; Cook J; Palmer JR; Romero DL; Tarpley WG; Salzman NP
    Virology; 1992 Sep; 190(1):269-77. PubMed ID: 1382341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
    Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Chong KT; Pagano PJ
    Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
    Balzarini J; Pérez-Pérez MJ; Vélazquez S; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5470-4. PubMed ID: 7539917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
    Balzarini J; Pelemans H; Aquaro S; Perno CF; Witvrouw M; Schols D; De Clercq E; Karlsson A
    Mol Pharmacol; 1996 Aug; 50(2):394-401. PubMed ID: 8700148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.